News

The procurement follows an 18-month pilot at a high-volume surgery in Dundee, Scotland

Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

Considering rapid increases in myopia, authors conducted a longitudinal cohort study of twins and their parents with the goal of exploring the intergenerational changes in the myopia epidemic in China.

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

A study reveals that repetitive head impacts in college football players do not significantly affect smooth pursuit eye movement velocity during a season.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EyeArt uses artificial intelligence for autonomous detection of vision-threatening diabetic retinopathy

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Canadian researchers reveal increased complications in cataract surgeries during the COVID-19 pandemic, highlighting risks and factors affecting outcomes.

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Conavi leverages ophthalmic imaging technology to enhance intravascular diagnostics in cardiology.

The partnership was announced in August of this year.

Justis Ehlers discusses promising results from the HELIOS trial, revealing a novel treatment for diabetic retinopathy that may reduce treatment frequency.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

The country has a goal of ensuring that more than 95% of patients with diabetes receive timely retinal examinations.